Memantine Treatment of Compulsive Buying
Information source: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Compulsive Buying
Intervention: Memantine (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: University of Minnesota - Clinical and Translational Science Institute Official(s) and/or principal investigator(s): Jon Grant, MD, Principal Investigator, Affiliation: University of Minnesota - Clinical and Translational Science Institute
Summary
This is an 8-week, open-labe study of memantine in the treatment of compulsive buying.
Clinical Details
Official title: Memantine Treatment of Compulsive Buying: An Open-Label Study
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS)
Detailed description:
The goal of the proposed study is to evaluate the efficacy of memantine in the treatment of
compulsive buying. Sixteen subjects meeting criteria for compulsive buying will receive 8
weeks of open-label memantine. The hypothesis to be tested is that memantine will be
effective and well tolerated in patients with compulsive buying. The proposed study will
provide needed data on the treatment of a disabling disorder that currently lacks a clearly
effective treatment.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. men and women age 18-65
2. current CB using the clinician-administered Structured Clinical Interview for
Compulsive buying (SCI-CB)
3. buying behavior within 2 weeks prior to enrollment
Exclusion Criteria:
1. infrequent buying (i. e. less than one time per week) that does not meet proposed
criteria for CB
2. unstable medical illness or clinically significant abnormalities on laboratory tests
or physical examination at screen
3. history of seizures
4. myocardial infarction within 6 months
5. current pregnancy or lactation, or inadequate contraception in women of childbearing
potential
6. a need for medication other than memantine with possible psychotropic effects or
unfavorable interactions;
7. clinically significant suicidality;
8. current Axis I disorder determined by the SCID and SCID-compatible modules for
impulse control disorders, except for nicotine dependence
9. lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any
psychotic disorder determined by SCID
10. current or recent (past 3 months) DSM-IV substance abuse or dependence;
11. positive urine drug screen at screening
12. initiation of psychotherapy or behavior therapy within 3 months prior to study
baseline
13. previous treatment with memantine
14. treatment with investigational medication or depot neuroleptics within 3 months, with
fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study
baseline
Locations and Contacts
Ambulatory Research Center, Minneapolis, Minnesota 55454, United States
University of Minnesota, Minneapolis, Minnesota 55454, United States
Additional Information
Impulse Control Disorders Clinic - University of Minnesota
Starting date: December 2008
Last updated: April 9, 2012
|